1. Steg P.G., James S.K., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619.
2. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128(16):e137-61.
3. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949-3003.
4. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28): 2159-219.
5. Uk J.M., UkH.D., Poland M.T., et al. Expert consensus document on β-adrenergic receptor blockersThe Task Force on Beta-Blockers ofthe European Society of Cardiology. EurHeartJ. 2004;25(15):1341-62.
6. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-St-ElevationAcute Coronary Syndromes.JAm Coll Cardiol. 2014;64(24):e139-228.
7. Opie L.H., Gersh B.J. Drug for the heart 8th edition. Philadelphia: Elsevier Saunders; 2013.
8. Boytsov S.A., Chuchalin A.G. Prevention of chronic non-infectious diseases. Guidelines. 2013. Available at: https://www.gnicpm.ru/UserFiles/Profilaktika_khronicheskikh_neinfekcionnykh_zabolevanijj.pdf. Checked by 08/17/2012. (In Russ.).
9. Halbert R.J., Natoli J.L., Gano A., et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-32.
10. MenezesA.M.B., Perez-Padilla R.,Jardim J.R.B., et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet. 2005;366(9500):1875-81.
11. The top 10 causes of death. Fact sheet, Updated January 2017. Geneva: World Health Organization; 2017.
12. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., etc. Experience of studying atrial fibrillation on the basis of the register PROFILE. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;13 (2):35-9. (In Russ.).
13. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., Zakharova A.V. Assessment of adherence to the use of new oral anticoagulants in patients with atrial fibrillation according to the PROFILE registry. Rational Pharmacotherapy in Cardiology. 2014;10(6):625-30. (In Russ.).
14. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., et al. Evaluation of the dynamics of prescribing antithrombotic agents in patients with atrial fibrillation according to the data of the PROFILE register. Kardiovaskulyarnaya Terapiya i Profilaktika.2015;14(1):35-40. (In Russ.).
15. Lukina Yu.V.,Dmitrieva N.A., Zakharova A.V., et al. Undesirable effects of drug therapy (the firstresults of the study according to the PROFILE outpatient registry. Rational Pharmacotherapy in Cardiology. 2016;12(3):306-13. (In Russ.).
16. Zagrebelny A.V., Martsevich S.Yu., Loukyanov M.M., et al. Assessment of the quality of prescription of antihypertensive drugs for patientswith arterial hypertensionwho do not have a combined cardiovascular pathology within the RECVASA outpatientregistry. Rational Pharmacotherapy in Cardiology. 2014; 10 (4): 378-83. (In Russ.).
17. Boytsov S.A., Loukyanov M.M., Yakushin S.S., et al. Registry of cardiovascular diseases (RECVASA): diagnostics, combined cardiovascular pathology, concomitant diseases and treatment in conditions of real outpatient and polyclinic practice. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;13(6):44-50. (In Russ.).
18. Boitsov S.A., Loukyanov M.M., Yakushin S.S., et al. RECVASA outpatient registкн: data from prospectiveobservation,risk assessment andoutcomes in patients with cardiovascular diseases. Kardiovaskulyarnaya Terapiya i Profilaktika. 2015;14(1):53-62. (In Russ.).
19. Martsevich S.Y., Kutishenko N.P., Tolpygina S.N., et al. Efficacy and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2011;7(5):2-72. (In Russ.).
20. Martsevich S.Yu., Zakharova N.A., Kutishenko N.P., et al. Study ofthe practice of prescribing beta-blockers and its correspondence to modern clinical recommendations within the framework of two outpatient registers of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2016;12(3):260-4 (In Russ.).
21. Martsevich S.Yu., Lukina Yu.V., Zagrebelny A.V., et al. Combined antihypertensive therapy in real clinical practice. Focus on fixed combinations of antihypertensive drugs (according to the data of RECVASA and PROFILE outpatient registries). Rational Pharmacotherapy in Cardiology. 2017;13(3):323-9 (In Russ.).
22. Quint J.K., Herrett E., Bhaskaran K., et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.
23. Lipworth B., SkinnerD.,Devereux G., et al. Underuse of β-blockers in heartfailure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909-14.
24. Tendera M., Fox K., Ferrari R., et al. Inadequate heartrate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014;176(1):119-24.
25. Order 520n from 15.07.2016 of the Ministry of Health of the Russian Federation. On the approval of criteria for assessing the quality of care. 2016. Available at: https://minjust.consultant.ru/documents/20356?items=1&page=1. Checked by 08/17/2012. (In Russ.).
26. Federal Law "On the circulation of medicines" of 12.04.2010 №61-FZ. Available at: www.consultant.ru/document/cons_doc_LAW_99350/. Checked by 08/17/2012. (In Russ.).